Summary & Overview

Vein Ligation and Stripping: Inpatient Reimbursement Overview

DRG 263 addresses inpatient admissions for vein ligation and stripping procedures used to treat varicose veins and related venous disorders. Understanding this Diagnosis-Related Group is important for inpatient reimbursement because it defines the bundled Medicare payment for the surgical episode and associated hospital resources.

Vein Ligation and StrippingDRG Vein Ligation and StrippingDRG 263Diagnosis-Related GroupInpatient ReimbursementMedicareVascular SurgeryPhlebologySurgical Procedures

DRG 263 Overview

DRG 263 covers inpatient admissions for vein ligation and stripping procedures, typically performed to treat varicose veins and venous insufficiency. This Diagnosis-Related Group captures the surgical procedure, associated perioperative care, and any included inpatient stay. It matters for Medicare payment because the bundled reimbursement reflects expected resource use for the operation and recovery, influencing hospital classification and payment for these cases. Payers and hospitals monitor this DRG to align coding, billing, and case mix considerations with payment policies.

National Payment Rates

Across commercial payers, negotiated rates range roughly from $370 to $90K, with payer medians spanning about $21K to $53K depending on insurer; the widest spread is seen between Anthem (min $390, max $90K) and Cigna (min $27K, max $87K). See the table and chart below for payer-specific distributions and quartiles. Payer-level medians highlight variation among Blue Cross Blue Shield, Cigna, Aetna, and Anthem.

Mean Rates by Payer — National — DRG 263

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska, mean rates for DRG 263 span from $48K to $74K across payers, with BCBS and Anthem clustered at $48K and Cigna markedly higher at $74K. This produces a wide state range driven mostly by Cigna’s higher mean, which deviates above several national benchmarks. See the table and chart below for payer-specific detail.

Key Insights for Alaska

Highest payer: Cigna at a mean of $74K; Lowest payers: BCBS and Anthem at a mean of $48K each.
Alaska’s payer mean range ($48K–$74K) shows Cigna paying notably above the state’s other payers and above national means for some payers, while BCBS and Anthem sit below or near national medians.

Clinical Trials

Surgical technique and perioperative complication reduction studies: trials comparing different operative approaches (open vein stripping versus minimally invasive ligation and endovenous thermal or non-thermal ablation adjuncts) or enhanced perioperative protocols focus on intraoperative blood loss, nerve injury, and wound infection rates. These studies enroll adult patients undergoing inpatient vein ligation and stripping for symptomatic varicose veins or venous insufficiency, often including those with large tributary varicosities or comorbidities that necessitate inpatient care. Results are directly relevant to surgeons and hospital administrators because they inform procedural choices, resource utilization, and short-term complication rates that drive length of stay and immediate reimbursement under DRG 263.
Comparative effectiveness and cost-consequence research across care settings: pragmatic trials and cohort studies comparing outcomes and total costs for inpatient vein ligation and stripping versus outpatient/ambulatory endovenous alternatives or staged hybrid procedures examine readmission, reintervention rates, and patient-reported symptom relief over 6–12 months. These studies typically enroll heterogeneous adult populations including older patients or those with cardiovascular or wound-healing comorbidities who might be preferentially treated as inpatients. Findings help payers and hospital finance teams assess whether shifting appropriate cases to outpatient pathways or selecting particular techniques reduces overall episode cost while maintaining quality, thus impacting authorization and bundled payment decisions for DRG-associated episodes.
Post-discharge functional outcomes and long-term recurrence studies: observational cohorts and registry-based research tracking wound healing, venous ulcer recurrence, chronic pain, and quality-of-life measures for 1–3 years after inpatient vein procedures focus on durability of symptom relief and late complications such as recurrent varicosities or chronic venous insufficiency progression. These studies target patients with advanced disease, venous ulcers, or significant comorbidity profiles who often generate higher post-acute care needs and follow-up utilization. The evidence informs clinicians and payers about expected long-term resource use, surveillance intervals, and potential need for additional interventions that influence total cost of care and readmission penalties tied to episodes initiated under DRG 263.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$29K	$140K	$21K	220

Surgical technique and perioperative complication reduction studies: trials comparing different operative approaches (open vein stripping versus minimally invasive ligation and endovenous thermal or non-thermal ablation adjuncts) or enhanced perioperative protocols focus on intraoperative blood loss, nerve injury, and wound infection rates. These studies enroll adult patients undergoing inpatient vein ligation and stripping for symptomatic varicose veins or venous insufficiency, often including those with large tributary varicosities or comorbidities that necessitate inpatient care. Results are directly relevant to surgeons and hospital administrators because they inform procedural choices, resource utilization, and short-term complication rates that drive length of stay and immediate reimbursement under DRG 263.
Comparative effectiveness and cost-consequence research across care settings: pragmatic trials and cohort studies comparing outcomes and total costs for inpatient vein ligation and stripping versus outpatient/ambulatory endovenous alternatives or staged hybrid procedures examine readmission, reintervention rates, and patient-reported symptom relief over 6–12 months. These studies typically enroll heterogeneous adult populations including older patients or those with cardiovascular or wound-healing comorbidities who might be preferentially treated as inpatients. Findings help payers and hospital finance teams assess whether shifting appropriate cases to outpatient pathways or selecting particular techniques reduces overall episode cost while maintaining quality, thus impacting authorization and bundled payment decisions for DRG-associated episodes.
Post-discharge functional outcomes and long-term recurrence studies: observational cohorts and registry-based research tracking wound healing, venous ulcer recurrence, chronic pain, and quality-of-life measures for 1–3 years after inpatient vein procedures focus on durability of symptom relief and late complications such as recurrent varicosities or chronic venous insufficiency progression. These studies target patients with advanced disease, venous ulcers, or significant comorbidity profiles who often generate higher post-acute care needs and follow-up utilization. The evidence informs clinicians and payers about expected long-term resource use, surveillance intervals, and potential need for additional interventions that influence total cost of care and readmission penalties tied to episodes initiated under DRG 263.

OpenPayer

Summary & Overview

Vein Ligation and Stripping: Inpatient Reimbursement Overview

DRG 263 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes